US5128152A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Iron-containing compositions and method for treating cancer
Assignee: Efamol Ltd
•
Filing: 1991-06-03
•
Granted: 1992-07-07
•
Expires: 2011-06-03
Abstract
Abstract Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.
Inventors
- 👤 David F. Horrobin
- 👤 Michel E. Begin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 22:26
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61K33/00; A61K33/24; A61K33/26; A61P; A61P35/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
105 words
A method of treating cancers sensitive to treatment with the combination of gamma-linolenic acid or dihomo-gamma-linolenic acid or both in an amount of 1 mg of 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g (calculated as iron) daily comprising administering to a person requiring such treatment said combination of gamma-linolenic acid, dihomo-gamma-linolenic acid of both, as such or as the molar equivalent amount of a compound convertible in the body thereto, and said iron compound, wherein the weight ratio of said fatty acid component to said iron component is about 1:2.
Claim 2
Independent Claim
105 words
A method of treating cancers sensitive to treatment with the combination of gamma-linolenic acid or dihomo-gamma-linolenic acid or both in an amount of 1 mg of 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g (calculated as iron) daily comprising administering to a person requiring such treatment said combination of gamma-linolenic acid, dihomo-gamma-linolenic acid of both, as such or as the molar equivalent amount of a compound convertible in the body thereto, and said iron compound, wherein the weight ratio of said fatty acid component to said iron component is about 1:2.
Claim 3
Dependent Claim
30 words
The method according to claim 1, in which the amounts of said iron are 5 mg to 500 mg and of said acid is 50 mg to 10 g daily.
Claim 4
Dependent Claim
27 words
The method according to claim 1 or 2, wherein said essential fatty acid is selected from the group consisting of gamma-linolenic acid, dihomo-gamma-linolenic acid and eicosapentanoic acid.
Claim 5
Independent Claim
114 words
A method of treating cancers sensitive to treatment with an essential fatty acid selected from gamma-linolenic acid, dihomo-gamma-linolenic acid, 20:5 delta-5,8,11,14,17 eicosapentaenoic acid and 2:6 delta-4,7,10,13,16,19 docosahexaenoic acid or combinations thereof in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g (calculated as iron) daily, comprising administering to a person requiring such treatment said combination of selected essential fatty acid(s) as such or as the molar equivalent amount of compound(s) convertible in the body thereto, and said iron compound, wherein the weight ratio of said fatty acid component to said iron component of about 1:2.
Claim 6
Independent Claim
114 words
A method of treating cancers sensitive to treatment with an essential fatty acid selected from gamma-linolenic acid, dihomo-gamma-linolenic acid, 20:5 delta-5,8,11,14,17 eicosapentaenoic acid and 2:6 delta-4,7,10,13,16,19 docosahexaenoic acid or combinations thereof in an amount of 1 mg to 100 g daily and an assimilable iron compound capable of damaging cancer cells in an amount of 0.1 mg to 1 g (calculated as iron) daily, comprising administering to a person requiring such treatment said combination of selected essential fatty acid(s) as such or as the molar equivalent amount of compound(s) convertible in the body thereto, and said iron compound, wherein the weight ratio of said fatty acid component to said iron component of about 1:2.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-07-07 | 1996-01-06 | 1996-07-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-07-07 | 2000-01-06 | 2000-07-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-07-07 | 2004-01-06 | 2004-07-07 | $7700.00 | Window Closed / Lapsed |